Aim Immunotech 주식 가격. 0A4Y - 주식 시세, 차트, 과거 거래, 주식 채팅, 재무.

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

프리미엄

가격

매수가

매도가

거래량

0.00 일간 변동폭 0.00

0.00 52주 범위 0.00

market_cap

전일 종가

개장가

최근 거래 시간

마지막 거래 시간

재정 규모

VWAP

평균 볼륨(3m)

발행 주식

48,842,000

배당수익률

주가수익률

-3.04

주당순이익(EPS)

-0.59

매출

202k

순이익

-28.96M

섹터

Biological Pds,ex Diagnstics

산업

Biological Pds,ex Diagnstics

웹사이트

www.aimimmuno.com

본부

Wilmington, Delaware, USA

설립됨

Aim Immunotech Inc is listed in the Biological Pds,ex Diagnstics sector of the 런던증권거래소 with ticker 0A4Y. The last closing price for Aim Immunotech was -. Over the last year, Aim Immunotech shares have traded in a share price range of US$ 0.00 to US$ 0.00.

Aim Immunotech currently has 48,842,000 shares in issue. Aim Immunotech has a price to earnings ratio (PE ratio) of -3.04.

AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza

AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian...

AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue

AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition...

AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic...

AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast

AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast OCALA, Fla., May 09, 2024...

AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®

AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen® OCALA, Fla., May 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc...

AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for...

AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer

AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the...

AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update Year marked by growing body of promising...

AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast

AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast OCALA, Fla...

AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research

AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal...

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

0A4Y - Frequently Asked Questions (FAQ)

What is the current Aim Immunotech share price?

The current share price of Aim Immunotech is US$ 0.00

How many Aim Immunotech shares are in issue?

Aim Immunotech has 48,842,000 shares in issue

What is the 1 year trading range for Aim Immunotech share price?

Aim Immunotech has traded in the range of US$ 0.00 to US$ 0.00 during the past year

What is the PE ratio of Aim Immunotech?

The price to earnings ratio of Aim Immunotech is -3.04

What is the cash to sales ratio of Aim Immunotech?

The cash to sales ratio of Aim Immunotech is 439.02

What is the reporting currency for Aim Immunotech?

Aim Immunotech reports financial results in USD

What is the latest annual turnover for Aim Immunotech?

The latest annual turnover of Aim Immunotech is USD 202k

What is the latest annual profit for Aim Immunotech?

The latest annual profit of Aim Immunotech is USD -28.96M

What is the registered address of Aim Immunotech?

The registered address for Aim Immunotech is 251 LITTLE FALLS DRIVE, NEW CASTLE, WILMINGTON, DELAWARE, 19808

What is the Aim Immunotech website address?

The website address for Aim Immunotech is www.aimimmuno.com

Which industry sector does Aim Immunotech operate in?

Aim Immunotech operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

가장 활성
% 상승자
% 패자

기호	가격	볼륨
WSGWestminster Group Plc	1.40p (27.27%)	2.57M
WHRWarehouse Reit Plc	98.80p (16.51%)	5.43M
MET1Metals One Plc	0.575p (15.00%)	1.8M
ZENZenith Energy Ltd.	7.75p (14.81%)	1.97M
CORCorpus Resources Plc	0.016p (14.29%)	186.59M
SAVESavannah Energy Plc	9.30p (-64.57%)	160.62M
VELAVela Technologies Plc	0.003p (-40.00%)	852.85M
TIGTeam Internet Group Plc	59.20p (-39.96%)	3.25M
ALBAAlba Mineral Resources	0.014p (-24.32%)	80.81M
SYMESupply@me Capital Plc	0.003p (-23.08%)	19.14M
VELAVela Technologies Plc	0.003p (-40.00%)	852.85M
TRPTower Resources Plc	0.023p (-2.13%)	201.66M
CORCorpus Resources Plc	0.016p (14.29%)	186.59M
SAVESavannah Energy Plc	9.30p (-64.57%)	160.62M
TOMTomco Energy Plc	0.0425p (-19.05%)	149.88M

gedi8 2 분 전

We will see my friend. His first month in office has really hurt the market. I hope you are right

NXPL

WooptdooU 3 분 전

Why don't these GRIFTERS use their OWN money and buy at the market.... they are NOT AFRAID of the helplessly hopeful pennylongs.

LWLG

louieforpar 3 분 전

Less than four one way or another.

glenn1919 4 분 전

INLF....................................................................................p/m

INLF

uranium-pinto-beans 5 분 전

OKTA
Okta upgraded to Buy from Neutral at DA Davidson
DA Davidson analyst Rudy Kessinger upgraded Okta to Buy from Neutral with a price target of $125, up from $90. The company reported "very strong" Q4 results and meaningfully raised its fiscal 2026 guidance, the analyst tells inve

OKTA

WooptdooU 5 분 전

These scummy insiders have done NOTHING but TAKE...they must believe the helplessly hopeful pennylongs are harmless to them.

LWLG

uranium-pinto-beans 7 분 전

mmmm

https://www.bloomberg.com/news/articles/2025-03-03/citi-copy-paste-error-almost-sent-6-billion-to-wealth-account

uranium-pinto-beans 8 분 전

OKTA
Okta price target raised to $100 from $94 at Canaccord
Canaccord raised the firm's price target on Okta to $100 from $94 and keeps a Hold rating on the shares. The firm said they reported resoundingly positive Q4 results ahead of both the firm's and consensus expectations with

OKTA

uranium-pinto-beans 8 분 전

MCHP
Microchip cyclical bottom may be forming, says JPMorgan

Jefedejefes 9 분 전

listening to your favorite song... over, and over, and over https://www.youtube.com/watch?v=BfnjX88Va4Y

EDXC

docj 13 분 전

"One example: the current CEO of Cytodyn was CMO under Nader Pourhassan the Frauder, and was fine with all his actions."

That is a false statement. It is a matter of public record how Dr JL felt about Nader. Stop trying to make it look like he was complicit with Nader's actions. It lo

CYDY

meixatech 14 분 전

"Oral bioavailability" is one of the most important properties in drug design and development. A high oral bioavailability reduces the amount of an administered drug necessary to achieve a desired pharmacological effect and therefore could reduce the risk of side-effects and toxicity.

RSPI

trader53 14 분 전

Nixon's Restaurants have not gone belly up

https://investorshub.advfn.com/uicon/155361.png?cb=636360310707230000
______________________________________________________________________

Nixon Restaurant Group Inc
is operated in Colorado ,

gp22 15 분 전

$ESLA @ $1.05....Given $16 one year target last week by highly regarded bio/pharma ETF...Hit $1.80s 2 weeks ago and backed off..$ESLA a repeat of Immuno $IOVA & $SMMT monster moves
Link: 9/29/24
https://finance.yahoo.com/news/estrella-immunopharma-achieves-complete-response-160000432.h

ESLA IOVA SMMT

WooptdooU 16 분 전

Grifter siraj...eom

LWLG

StockWorkOrange 19 분 전

Aw. Someone is upset their Picture Pump didn't work this time. Oh well. I'm sure you'll come up with something new to get these bAABBoons to hand over some more money.......

AABB

hedge_fun 20 분 전

They’ll need to be careful with their…….,

updates, won’t they?

They say the device pinpoints treasure, right?

If they’re diving and coming up empty, then Houston, don’t we have a problem?

Of course they could always be doing something wit

SFRX

StockWorkOrange 20 분 전

We all see how well you and the pump crew are doing on X with your 20 likes. Keep up the good work Alidare. It really seems to be working......#ticktock

AABB

glenn1919 20 분 전

AEON.......SPPL........RETO........PTIX.........................................................................p/m

PTIX RETO SPPL

WeTheMarket 21 분 전

UK, any comments on the Earnings Report/10K? Are you still out and plan to stay out or do you see signs of hope for the future?

PLUG

glenn1919 22 분 전

AEON..........................................https://stockcharts.com/h-sc/ui?s=AEON&p=W&b=5&g=0&id=p86431144783

AEON

Jackxkr 23 분 전

At this moment what happens after approval is not as worrying as getting approval. As each day passes chances of approval goes down from here.

NWBO

edbi46 25 분 전

On REDDIT 3 months ago:
RecoveryRx now available through prosthetics for pain management, ortho, PT
Veterans Health Administration
VA providers now have access to recently FDA-approved non-opioid, non-invasive pain management device through RecoveryRx. RecoveryRx produces an el

BMI LMT QUBT

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

Aim Immunotech Inc (0A4Y)

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

주요 통계 및 세부정보

Aim Immunotech Inc 정보

0A4Y 최신 뉴스

AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza

AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue

AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast

AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®

AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer

AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast

AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research

AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza

AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue

AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast

AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®

AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer

AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

0A4Y - Frequently Asked Questions (FAQ)

이동자

토론

최근 히스토리

회사 소개

사업

Popular

앱 받기

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

Aim Immunotech Inc (0A4Y) 시세

Aim Immunotech Inc (0A4Y)

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

주요 통계 및 세부정보

Aim Immunotech Inc 정보

0A4Y 최신 뉴스

AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza

AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue

AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast

AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®

AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer

AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast

AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research

AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza

AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue

AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast

AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®

AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer

AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

0A4Y - Frequently Asked Questions (FAQ)

이동자

토론

최근 히스토리

회사 소개

사업

Popular

앱 받기

광고 제거

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE